Wechselwirkungen · Epclusa
Epclusa 200 mg/50 mg coated granules in sachet Epclusa 150 mg/37.5 mg coated granules in sachet · Abschnitt 4.5 · PDF-Seite 42
HOS-136193 · Präparat HOS-097846
Patients receiving tenofovir disoproxil fumarate and Epclusa concomitantly should be monitored for adverse reactions associated with tenofovir disoproxil fumarate. Refer to the tenofovir disoproxil fumarate-containing product’s Summary of Product Characteristics for recommendations on renal monitoring (see section 4.4). Efavirenz/ emtricitabine/ Efavirenz ↔ ↔ ↔ Co-administration of Epclusa with tenofovir disoproxil Sofosbuvir ↑ ↔ efavirenz/ emtricitabine/ tenofovir fumarate 1.4 disoproxil fumarate is expected to (600/ 200/ 300 mg once (1.1, decrease the concentration of daily)/ sofosbuvir/ 1.7) velpatasvir. Co-administration of velpatasvir (400/ 100 mg Velpatasvir ↓ ↓ ↓ Epclusa with efavirenz-containing once daily)c, d 0.53 0.47 0.43 regimens is not recommended (see (0.43, (0.39, (0.36, section 4.4). 0.64) 0.57) 0.52)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) tenofovir disoproxil (HOS-108843) fumarate (HOS-108845) efavirenz (HOS-087947) tenofovir disoproxil fumarate (HOS-110471) emtricitabine (HOS-085840)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-08-14T16:16:00Z · SHA-256 5a15459ef6523a9cfa2e141592af073eabefab68f2b8f9dc006f477858a7fe66 · Passage 0fd7c99e8a73499e6bfe64ff8b88d0a5885c10e390dcd5b9f01c4efc967f9f95 · Zeichen 16858–18238 im Abschnitt